Compare Ascendis Pharma A/S (ASND) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Nutanix Inc — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Nutanix Inc trades at $55.6 (market cap $14.81B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| ASND | NTNX | |
|---|---|---|
Market Cap | $17.74B | $14.81B |
Sector | Health | Technology |
52-Week High | $277.18 | $81.12 |
52-Week Low | $163.32 | $34.41 |
Enterprise Value | $18.11B | $14.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Nutanix (NTNX) trades at $54.79, down 1.33% on the day, with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals, with Q1 2026 EPS of $0.47 beating expectations and a robust gross profit margin of 87.09%. Recent news highlights momentum, including NVIDIA certification for its storage solution and positive analyst coverage.
The outlook is positive, driven by consistent earnings beats, expanding AI infrastructure opportunities, and a consensus price target of $57.80. Key risks include high valuation multiples and competitive pressures in the hybrid cloud market. Wall Street sentiment is bullish, with 62.5% of analysts rating the stock a Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
